It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is a matter of investigation and its diagnosis remains challenging. Although the mechanisms that are responsible for the development of HFpEF are not fully understood, it is well known that nearly 80% of patients with HFpEF have concomitant hypertension. We investigated whether early biochemical alterations were detectable during HFpEF progression in salt-induced hypertensive rats, using Fourier-transformed infrared (FTIR) and Raman spectroscopic techniques as a new diagnostic approach. Greater protein content and, specifically, greater collagen deposition were observed in the left atrium and right ventricle of hypertensive rats, together with altered metabolism of myocytes. Additionally, Raman spectra indicated a conformational change, or different degree of phosphorylation/methylation, in tyrosine-rich proteins. A correlation was found between tyrosine content and cardiac fibrosis of both right and left ventricles. Microcalcifications were detected in the left and right atria of control animals, with a progressive augmentation from six to 22 weeks. A further increase occurred in the left ventricle and right atrium of 22-week salt-fed animals, and a positive correlation was shown between the mineral deposits and the cardiac size of the left ventricle. Overall, FTIR and Raman techniques proved to be sensitive to early biochemical changes in HFpEF and preceded clinical humoral and imaging markers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Perugia, Department of Chemistry, Biology and Biotechnology, Perugia, Italy (GRID:grid.9027.c) (ISNI:0000 0004 1757 3630)
2 Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research (IEMR), Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, KG Jebsen Centre for Cardiac Research, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); University of Mississippi Medical Center, Department of Pathology, School of Medicine, Jackson, USA (GRID:grid.410721.1) (ISNI:0000 0004 1937 0407)
3 Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research (IEMR), Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, KG Jebsen Centre for Cardiac Research, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
4 American University of Beirut Medical Center, Department of Pharmacology and Toxicology, Faculty of Medicine, Beirut, Lebanon (GRID:grid.411654.3) (ISNI:0000 0004 0581 3406)
5 American University of Beirut Medical Center, Department of Pharmacology and Toxicology, Faculty of Medicine, Beirut, Lebanon (GRID:grid.411654.3) (ISNI:0000 0004 0581 3406); American University of Beirut Medical Center, The Cardiovascular, Renal, and Metabolic Diseases Center of Excellence, Beirut, Lebanon (GRID:grid.411654.3) (ISNI:0000 0004 0581 3406); University of Mississippi Medical Center, Department of Pharmacology and Toxicology, School of Medicine, Jackson, USA (GRID:grid.410721.1) (ISNI:0000 0004 1937 0407)
6 University of Oslo, Department of Molecular Medicine, Institute for Basic Medical Sciences, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
7 University of Mississippi Medical Center, Department of Pharmacology and Toxicology, School of Medicine, Jackson, USA (GRID:grid.410721.1) (ISNI:0000 0004 1937 0407)




